Avelumab Fails to Extend PFS in Ovarian Cancer

January 2, 2019 5:00 pm

A randomized phase 3 trial designed to evaluate avelumab for women with previously untreated advanced ovarian cancer failed to achieve its primary endpoint of PFS.

The JAVELIN Ovarian 100 study has been terminated based on the finding, reported as part… Read more

FDA Approves Lynparza for Maintenance Treatment of BRCA-Mutant Gynecologic Cancers

December 19, 2018 5:00 pm

By Brielle Benyon

The Food and Drug Administration (FDA) approved Lynparza (olaparib) for the maintenance treatment of adults with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in a

Read more

What Are My Options for Ovarian Cancer Treatment?

December 15, 2018 9:00 am

By Korin Miller

Navigating ovarian cancer treatment options can be overwhelming, but if you have this illness, it’s a part of the process.

There are five major forms of treatment for ovarian cancer. However, the type of ovarian cancer you … Read more

Many Americans Unaware of Promise of Targeted, ‘Personalized’ Medicine

December 7, 2018 7:00 pm

By Dennis Thompson

Medical science has made tremendous advances in “personalized medicine” — drugs that fight cancer and other diseases by boosting the immune system or targeting specific genetic traits.

Former U.S. President Jimmy Carter benefited from one of these

Read more

From Standard to Personalised Care

November 17, 2018 7:00 pm

Woman with ovarian cancer has incredible response to treatment selected based on her tumor molecular profile. This tumor testing is part of the tumor blueprint that Clearity provides.

By Pierre Valette

“It was definitely a ‘holy smokes’ moment,” recounts Justin … Read more

Nearly Half of Americans Think Alternative Medicine Can Cure Cancer. It Can’t.

October 30, 2018 9:39 pm

By Rachael Rettner

Many Americans hold the misguided view that alternative therapies alone can cure cancer, even though such methods are not proven to be effective in treating cancer, according to a new survey.

The survey, known as the National … Read more

Real-World Experience Differs from Trial Results for Niraparib in Recurrent Ovarian Cancer

October 25, 2018 1:11 am

By 

Real-world experience of adverse events with the oral PARP inhibitor niraparib in patients with platinum-sensitive recurrent ovarian cancer at a 200 mg daily dose differed from those most commonly seen in the phase 3 clinical trial at … Read more

Ovarian Cancer ‘Breakthrough’ Drug Prevents Disease Returning for Years

October 22, 2018 4:35 pm

By 

A new ovarian cancer treatment dramatically reduces the chances of the disease returning, a study has shown.

Doctors have hailed the results of a “breakthrough” trial which they say opens the possibility that many more women suffering … Read more

New Blood Test Could Spare Cancer Patients From Unnecessary Chemotherapy

October 17, 2018 10:02 pm

Cancer patients could be spared unnecessary chemotherapy – and its side effects – by a new blood test that is in clinical trials at more than 40 hospitals in Australia and New Zealand.

The trials, led by Melbourne researchers, are … Read more

Ovarian Cancer Thwarts Immune Cells by Revving up Stress

October 12, 2018 11:30 pm

Ovarian tumors disable the immune system’s killer T cells—which protect the body by destroying infected or malignant cells—enabling the disease to flourish unchecked, according to a new study by Weill Cornell Medicine scientists. The findings show that adverse conditions within … Read more

Early Clinical Trials Showing Promise for New Kind of Cancer Vaccine

September 30, 2018 3:14 pm

By Rich Haridy

Promising early results are in from a phase 1 clinical trial into the safety and efficacy of a new cancer vaccine. The new treatment is designed to stimulate the immune system into attacking certain cancers known to … Read more

BRCA1 Methylation Level May Predict Which Ovarian Cancer Patients Respond to PARP Inhibitors

September 28, 2018 8:37 pm

The extent to which the BRCA1 promoter is methylated could signal an ovarian tumor’s susceptibility to PARP inhibitor treatment, a new study has found.

PARP inhibitor treatment has been effective in treating some patients with high-grade serous ovarian carcinoma with … Read more

Novel Biomarker Found in Ovarian Cancer Patients Can Predict Response to Therapy

September 27, 2018 6:58 pm

Despite months of aggressive treatment involving surgery and chemotherapy, about 85 percent of women with high-grade wide-spread ovarian cancer will have a recurrence of their disease. This leads to further treatment, but never to a cure. About 15 percent of

Read more

CTLA4 Targeted Therapy Plus PD-1 Targeted Therapy Could Benefit Women With Ovarian Cancer

September 19, 2018 12:22 am

An analysis of the NRG Oncology clinical trial NRG-GY003 suggests that adding ipilimumab, a monoclonal antibody that targets the protein receptor CTLA-4, to a regimen with the checkpoint inhibitor nivolumab could improve the proportion with tumor response and progression-free survival … Read more

New Developments in Ovarian Cancer Treatment Are Showing Promise

September 14, 2018 4:29 pm

Cancer is never an easy foe, but some types are more stubborn than others. Ovarian cancer is one of the hardest to treat.

But there are signs of progress. Several recent studies have used new combination treatment strategies, including a … Read more

Drug Combination Gives ‘Exciting’ Results in Ovarian and Lung Cancer in Early Trial

August 24, 2018 1:58 am

Combining a new targeted cancer drug with chemotherapy has shown promise in an early clinical trial, in patients with ovarian or lung cancer for whom all other treatments had failed.

The combination of targeted drug vistusertib along with paclitaxel chemotherapy … Read more

Tumor Treating Fields Plus Paclitaxel Appears Safe, Effective in Recurrent Ovarian Cancer

August 16, 2018 12:57 am
BY Kristie L. Kahl
The combination use of Tumor Treating Fields (TTFields) and paclitaxel more than doubled progression-free survival (PFS) in patients with recurrent, platinum-resistant ovarian cancer compared with those who received weekly paclitaxel, according to results from the phase … Read more

Taking A Wider View Of Precision Oncology

August 6, 2018 11:06 pm

Proponents of precision medicine cite the growing numbers of successful precision cancer drugs. The examples of Herceptin (trastuzumab), Gleevec (imatinib mesylate), Xalkori (crizotinib), and Zelboraf (vemurafenib) come to mind. Skeptics, on the other hand, focus on the … Read more

Quality of Life Maintained With Niraparib for Ovarian Cancer

August 1, 2018 9:19 pm

by Madeline Marr

The use of niraparib in women receiving treatment for platinum-sensitive recurrent ovarian cancer did not adversely affect quality of life (QoL), according to a study published in The Lancet Oncology.

An international team of researchers led … Read more

Treating Ovarian Cancers by Targeting Mutations

July 31, 2018 11:22 pm

New research has shown that ovarian cancer patients with a tumor mutation in the BRAF gene respond exceptionally well to treatment with targeted drugs, known as BRAF inhibitors.

BRAF inhibitors block the activity of mutated BRAF gene. They are currently … Read more